ASCO GU 2026: Updates in bladder cancer

ASCO GU 2026: Updates in metastatic prostate cancer

ASCO GU 2026: Updates in localised prostate cancer

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and heterogeneous treatment patterns

Evaluation and definition of response and progression from trials to clinical practice

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma

Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies

Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma

FFX/bevacizumab plus atezolizumab improves PFS in first-line dMMR/MSI-H mCRC